These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35371270)

  • 61. Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.
    Bachert C; Maurer M
    Clin Drug Investig; 2010; 30(2):109-22. PubMed ID: 20067329
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-term safety and efficacy of bilastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with allergic rhinitis: Results of an open-label trial.
    Okubo K; Gotoh M; Togawa M; Saito A; Ohashi Y
    Auris Nasus Larynx; 2017 Jun; 44(3):294-301. PubMed ID: 27561709
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects.
    Togawa M; Yamaya H; Rodríguez M; Nagashima H
    Clin Drug Investig; 2016 Dec; 36(12):1011-1021. PubMed ID: 27498100
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bilastine and the central nervous system.
    Montoro J; Mullol J; Dávila I; Ferrer M; Sastre J; Bartra J; Jáuregui I; del Cuvillo A; Valero A
    J Investig Allergol Clin Immunol; 2011; 21 Suppl 3():9-15. PubMed ID: 22185045
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ebastine in the Treatment of Allergic Rhinitis and Urticaria: 30 Years of Clinical Studies and Real-World Experience.
    Sastre J
    J Investig Allergol Clin Immunol; 2020; 30(3):156-168. PubMed ID: 30977465
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis.
    Phinyo P; Koompawichit P; Nochaiwong S; Tovanabutra N; Chiewchanvit S; Chuamanochan M
    J Allergy Clin Immunol Pract; 2021 Feb; 9(2):956-970.e57. PubMed ID: 32916325
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
    Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
    Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers.
    Farré M; Pérez-Mañá C; Papaseit E; Menoyo E; Pérez M; Martin S; Bullich S; Rojas S; Herance JR; Trampal C; Labeaga L; Valiente R
    Br J Clin Pharmacol; 2014 Nov; 78(5):970-80. PubMed ID: 24833043
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bilastine: an environmental risk assessment.
    Lucero ML; Peither A; Ledo F
    Drug Chem Toxicol; 2015 Oct; 38(4):460-8. PubMed ID: 25609003
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bilastine as a potential treatment in allergic rhinitis.
    Kowal K; DuBuske L
    Am J Rhinol Allergy; 2014; 28(4):312-6. PubMed ID: 25197918
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study.
    Kuna P; Bachert C; Nowacki Z; van Cauwenberge P; Agache I; Fouquert L; Roger A; Sologuren A; Valiente R;
    Clin Exp Allergy; 2009 Sep; 39(9):1338-47. PubMed ID: 19438584
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study.
    Maurer M; Houghton K; Costa C; Dabove F; Ensina LF; Giménez-Arnau A; Guillet G; Konstantinou GN; Labrador-Horrillo M; Lapeere H; Meshkova R; Pastorello EA; Velásquez-Lopera M; Tamayo Quijano LM; Vestergaard C; Chapman-Rothe N
    World Allergy Organ J; 2018; 11(1):32. PubMed ID: 30464782
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Giordano-Labadie F; Becherel PA; Pralong P; Outtas O; Ruer-Mulard M; Berard F; Greco M; Lacour JP; Debons-Peyroutet M; Pelvet B; Lamirand A; Guillet G
    Eur J Dermatol; 2021 Apr; 31(2):217-224. PubMed ID: 34001470
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study.
    Thomsen SF; Pritzier EC; Anderson CD; Vaugelade-Baust N; Dodge R; Dahlborn AK; Vestergaard C
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1048-1055. PubMed ID: 28294420
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The global burden of chronic urticaria for the patient and society.
    Gonçalo M; Gimenéz-Arnau A; Al-Ahmad M; Ben-Shoshan M; Bernstein JA; Ensina LF; Fomina D; Galvàn CA; Godse K; Grattan C; Hide M; Katelaris CH; Khoshkhui M; Kocatürk E; Kulthanan K; Medina I; Nasr I; Peter J; Staubach P; Wang L; Weller K; Maurer M
    Br J Dermatol; 2021 Feb; 184(2):226-236. PubMed ID: 32956489
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of bilastine on chronic spontaneous urticaria refractory to levocetrizine: Real world experience in India.
    Shah B; De A; Sarda A; Kochhar AM; Dhoot D; Deshmukh G; Barkate H
    Dermatol Ther; 2021 Jan; 34(1):e14557. PubMed ID: 33210404
    [No Abstract]   [Full Text] [Related]  

  • 77. Oral availability of bilastine.
    Sádaba B; Gómez-Guiu A; Azanza JR; Ortega I; Valiente R
    Clin Drug Investig; 2013 May; 33(5):375-81. PubMed ID: 23529786
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Differential Regulation of Bilastine Affinity for Human Histamine H
    Akimoto H; Sugihara M; Hishinuma S
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562121
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses.
    Zuberbier T
    J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):9-18. PubMed ID: 21797930
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Interactions of bilastine, a new oral H₁ antihistamine, with human transporter systems.
    Lucero ML; Gonzalo A; Ganza A; Leal N; Soengas I; Ioja E; Gedey S; Jahic M; Bednarczyk D
    Drug Chem Toxicol; 2012 Jun; 35 Suppl 1():8-17. PubMed ID: 22616811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.